SCM
ALNY icon

Southport Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Southport Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,175
Closed -$708K – 225
2021
Q4 		$708K Buy
+4,175
New +$776K 0.12% 168

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Southport Capital Management's ALNY Position: Q1 2022 in Review

Southport Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 4,175 shares — an estimated $708K sold.

Southport Capital Management first reported a position in ALNY in Q4 2021 and held it in 1 quarter. The position peaked at $708K in Q4 2021. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • Southport Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Southport Capital Management sold 4,175 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $708K.
  • Southport Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Southport Capital Management's Alnylam Pharmaceuticals position peaked at $708K in Q4 2021.
  • 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Southport Capital Management's 13F filing for Q1 2022, filed 25 Apr 2022.